Siemens Fonds Invest GmbH Purchases 18,060 Shares of Cencora, Inc. (NYSE:COR)

Siemens Fonds Invest GmbH raised its holdings in shares of Cencora, Inc. (NYSE:COR) by 944.6% in the 4th quarter, Holdings Channel reports. The institutional investor owned 19,972 shares of the company’s stock after purchasing an additional 18,060 shares during the quarter. Siemens Fonds Invest GmbH’s holdings in Cencora were worth $4,645,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of COR. Norges Bank bought a new position in Cencora in the 4th quarter valued at $478,309,000. Bank of America Corp DE boosted its stake in shares of Cencora by 62.3% during the fourth quarter. Bank of America Corp DE now owns 5,193,807 shares of the company’s stock valued at $1,166,944,000 after purchasing an additional 1,994,256 shares during the period. Castlekeep Investment Advisors LLC bought a new position in shares of Cencora in the fourth quarter worth about $399,508,000. Raymond James Financial Inc. purchased a new position in Cencora in the 4th quarter worth about $322,460,000. Finally, Invesco Ltd. lifted its holdings in Cencora by 20.4% during the 4th quarter. Invesco Ltd. now owns 3,243,531 shares of the company’s stock valued at $728,757,000 after buying an additional 550,246 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Bank of America upped their target price on shares of Cencora from $270.00 to $285.00 and gave the stock a “neutral” rating in a research note on Friday, April 11th. Robert W. Baird increased their price objective on Cencora from $314.00 to $350.00 and gave the stock an “outperform” rating in a research note on Thursday, May 8th. Morgan Stanley set a $288.00 price objective on Cencora in a report on Tuesday, April 15th. Wells Fargo & Company upped their target price on Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a report on Friday, March 14th. Finally, Evercore ISI raised their price target on Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $301.18.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 5,000 shares of the firm’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares of the company’s stock, valued at approximately $3,724,197.76. This trade represents a 24.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Lazarus Krikorian sold 2,000 shares of the business’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $260.06, for a total value of $520,120.00. Following the sale, the chief accounting officer now owns 20,154 shares in the company, valued at $5,241,249.24. The trade was a 9.03% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,223 shares of company stock worth $13,580,967 over the last three months. Corporate insiders own 10.80% of the company’s stock.

Cencora Trading Up 2.3%

COR opened at $285.51 on Friday. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The firm has a market cap of $55.37 billion, a price-to-earnings ratio of 40.61, a PEG ratio of 1.31 and a beta of 0.60. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $309.35. The stock has a fifty day moving average price of $278.51 and a 200-day moving average price of $254.58.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, topping analysts’ consensus estimates of $4.07 by $0.35. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The business had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. During the same period in the previous year, the company posted $3.80 earnings per share. The firm’s revenue was up 10.3% on a year-over-year basis. As a group, equities research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, June 2nd. Investors of record on Friday, May 16th will be given a dividend of $0.55 per share. The ex-dividend date is Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a yield of 0.77%. Cencora’s payout ratio is 25.52%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.